A micellar liquid chromatography (MLC) method using a C18 column was developed to determine three antiarrhythmic drugs-disopyramide, lidocaine, and quinidine-that are most usually monitored in serum samples. After the application of an interpretative strategy for optimization of dodecyl sulfate sodium (SDS) and modifier concentrations in order to ensure the minimum analysis time, maximum sensitivity, and good resolution, the optimum chromatographic conditions for the determination of the three antiarrhythmics were flow rate, 1 mL/min; injection volume, 20 mL; separation temperature, 25°C; mobile phase, 150 mmol/L SDS-7% (v/v) butanol-phosphate buffer, 10 mmol/L, pH 7-0.9% (w/v) NaCl; and detection at 214 nm. The calibration curves for the drugs were linear (r 2 > 0.999). The intraday and interday precisions were lower than 3.9% (CV). Recoveries were 100 ± 0.6% when the method was applied to both serum samples spiked with the antiarrhythmics (n = 10) and real serum samples. In all cases, the results were similar to those obtained using the reference method (fluorescence polarization immunoassay) usually employed in the hospital. [AU: STATE WHICH HOSPITAL] The proposed method is useful for hospital monitoring of the antiarrhythmics by direct injection into the chromatograph.
A ntiarrhythmics are used to treat arrhythmias and to prevent relapses. Their monitoring is very important because of the necessity to verify dosage compliance, and because the response in patients due to subtherapeutic and toxic concentrations are similar (1) . The most widely used antiarrhythmic drugs in Spanish hospitals are disopyramide, lidocaine, and quinidine (2, 3) . These drugs are also used to treat auricular and ventricular arrhythmias (4) .
These antiarrhythmics have been quantified by immunoassay (5) (6) (7) (8) , capillary electrophoresis (9) , and RP-HPLC (1, 10-18) with C18 (10, (12) (13) (14) (15) (16) or cyano (11, 17) columns and mobile phases with one or more organic solvents, such as methanol-acetic acid-triethylamine (15) , acetonitrile-triethylamine (10, 18) , acetonitrile-methanol (12) , acetonitrile (14, 16), acetonitrile-acetic acid-ammonium acetate (13, 19) , and tetrahydrofuran (17) . The use of RP-HPLC for analyzing biological samples is limited due to the need of sample pretreatment prior to analysis, which includes several steps, such as liquid-liquid extraction (14, 17) or SPE on a single-use cartridge (10, 16, 18) . These extraction procedures are time-consuming and expensive, with consumption of relatively large amounts of toxic organic solvents. In addition, they can introduce additional sources of errors. Thus, the present method can replace the previously reported methods for the determination of the above mentioned drugs satisfactorily.
Micellar liquid chromatography (MLC) is an RP-HPLC method (20) (21) (22) (23) (24) (25) (26) . In MLC, the mobile phase comprises a surfactant at a higher concentration than the critical micellar concentration and an organic modifier, such as propanol, butanol, or pentanol, that decreases the retention factor and increases efficiency. The exact prediction of solute retention is possible through micellar mobile phases by using a model that could also be used to optimize the separation of solute mixtures (22) . Over recent years, MLC has proven to be a useful technique for the analysis of diverse groups of drugs, including anticonvulsants (23), benzodiazepines (24) , barbiturates (25) , and stimulants (23) (24) (25) (26) in serum samples.
One of the main advantages of MLC is that it offers the possibility of determining drug residues in physiological fluids, such as blood, serum, etc., without removal of proteins present in the serum samples. Thus, the drug residues could be distributed freely in a stationary phase while the proteins, instead of being precipitated inside the column, are either eluted with the mobile phase front or shortly afterwards. The use of a surfactant with direct sample injection is also less complicated than column switching procedures (11) , in which additional instrumentation (precolumns, valves, and pump switching of the chromatograph) is required, as are the accuracy and precision of valve switching time. In comparison with other solvents, micellar mobile phases are less flammable, more economical, less toxic, and biodegradable, and they can cosolubilize hydrophobic and hydrophilic analytes inside a complex matrix, such as blood serum.
In this manuscript, we describe determination of antiarrhythmics by MLC in serum by means of direct injection. The purpose of this study was to verify the chromatographic performance of the three antiarrhythmics with a view to introduce a rapid and simple procedure for determining these drugs without the need to previously deproteinize samples. 
Experimental

Chemicals and Reagents
The drugs used in this work were disopyramide, lidocaine, and quinidine (Sigma-Aldrich Gmbh, Steinheim, Germany). Stock solutions containing 20 mg/L each drug were prepared for the chromatographic optimization studies by dissolving the analyte in methanol, which was subsequently and suitably diluted with 0.9% NaCl (w/v) solution in order to maintain the same ionic strength as that of the serum samples. The reagents used to prepare the micellar mobile phases were sodium dodecyl sulfate (SDS; 99% purity, 50-150 mmol/L), 1-propanol (2.5-12.5% v/v), 1-butanol (1-7% v/v), 1-pentanol (2-6% v/v), sodium chloride 0.9% (w/v), disodium hydrogen phosphate, and hydrochloride acid (Merck, Darmstadt, Germany). The standard solutions and the mobile phases were filtered through 0.45 mm nylon membranes with a diameter of 12 and 45 mm (Micron Separations, Westboro, MA), respectively. Distilled-deionized water (Barnstead, Sybron, Boston, MA) was used throughout.
Apparatus and Instrumentation
The chromatographic system used for all optimization, validation, and analyses was an Agilent Technologies Model 1100 (Palo Alto, CA) equipped with a quaternary pump; autosampler with 2 mL vials and fitted with a Rheodyne valve (Rohnert Park, CA); and diode array detector (range 190-700 nm). A Kromasil C18 column (5 mm particle size, 250 ´ 4.6 mm id; Scharlab, Barcelona, Spain) thermostated at 25°C was used in the separations. The flow rate, injection volume, and detection wavelength were 1 mL/min, 20 mL, and 214 nm, respectively. The signal was acquired by a personal computer connected to the chromatograph by means of Agilent Chemstation. These data were later treated using SPSS 17.0 software (SPSS Inc., Chicago, IL). A GLP 22 potentiometer (Crison, Barcelona, Spain) equipped with a combined Ag/AgCl/glass electrode was used to perform pH measurements. Whole blood samples, without anticoagulant, were centrifuged with a Sorvall RC-5B from DuPont Instruments (Wilmington, DE).
Serum Sample Preparation and Recommended Mobile Phases
Serum samples, corresponding to volunteer patients and healthy subjects, were provided by the Verge dels Lliris Hospital (Alcoi, Alacant, Spain) with permission of the Ethics Commission. The blood samples of the healthy volunteers were centrifuged for 10 min at 654 g to obtain serum samples that were stored at -21°C and then thawed just before use. Spiked serum samples were prepared by adding a suitable volume of the 20 mg/L stock solution to 1 mL prepared serum, and the volume was adjusted to 10 mL with the mobile phase 150 mmol/L SDS-7% (v/v) butanol-phosphate buffer, 10 mol/L, pH 7-0.9% (w/v) NaCl. The real serum samples containing drug residues were isolated from the blood samples of the volunteer patients in the same manner as described earlier, then diluted to a ratio of 1:10 with the mobile phase, also containing 0.9% (w/v) NaCl solution. All solutions were kept at 4°C until used within 1 week.
Finally, the serum samples (spiked and real) containing disopyramide, lidocaine, and quinidine were injected and chromatographed with the mobile phase and detection at 214 nm for their analysis.
Results and Discussion
Optimization Strategy and Mobile Phase Selection
The optimization procedure was performed under the criteria of maximum resolution, minimum analysis time, and good chromatographic parameters (22) . The variations in the concentration of SDS in the mobile phase modify the number of micelles in it and enhance the resolution of the drugs. One of the greatest disadvantages of HPLC using micellar liquid phases is the occurrence of peak broadening. The presence of small amounts of organic components in the mobile phase can have an important effect on the interaction between the micelles and the stationary phase. Short-chain alcohols used as organic modifiers (methanol, propanol, butanol, pentanol, and hexanol) produce a decrease in the retention factor and increase the efficiency of the solutes studied; however, the maximum concentration of these modifiers in the mobile phase was never higher than 10% in order to ensure the presence of sufficient micelles at all times. In order to optimize the mobile phase composition, the retention equation of the three selected antiarrhythmics in this study was obtained using a reduced (five) and selected number of mobile phases: four located at the corners of a rectangular factor space and the fifth in its center. The limits of the factor space (surfactant and alcohol) were SDS/pentanol (50/2, 50/6, 100/4, 150/2, 150/6), SDS/butanol (50/1, 50/7, 100/4, 150/1, 150/7), SDS/propanol (50/2.5, 50/12.5, 100/7.5, 150/2.5, 150/12.5) in mmol/L and % (v/v) concentrations, respectively, and SDS (pure micellar phase, 50, 100, and 150 mmol/L). All of these solutions were buffered with pH 7 phosphate buffer containing 0.9% (w/v) NaCl.
The peaks obtained using these mobile phases were used to perform measurements of retention time (t R ), retention factor (k), efficiency (N), and tailing factor (T f ; measured at 5% peak height) for the antiarrhythmics. These data were used together with a mathematical model and an interpretative optimization procedure in order to predict the resolution. In pure micellar mobile phases of SDS (with no modifier) or in SDS-propanol, the t R of the three antiarrhythmics were higher than 30 min. On the other hand, when SDS-pentanol mobile phases were used, the three antiarrhythmics peaks overlapped with the protein band, which takes up the first 3 min of a chromatogram. For these reason, the data obtained in SDS-butanol were used to select the most suitable mobile phase in the optimization procedure, which maximized the resolution in the separation of dysopyramide, lidocaine, and quinidine.
After optimization, the selected mobile phase was 150 mmol/L SDS-7% (v/v) butanol-phosphate buffer, pH 7-0.9% (w/v) NaCl, with detection at 214 nm. In this mobile phase, t R , k, N, and T f values were 3.7, 3.5, 3030, and 1.3 for disopyramide; 6.6, 7.3, 2500, and 0.9 for lidocaine; and 9.9, 10.6, 2100, and 1.2 for quinidine, respectively.
Direct Injection of Serum Samples
When serum samples are injected directly into a micellar chromatographic system, interferences may occur initially owing to the endogen substances of physiological origin, and also as a consequence of the presence of plasma proteins. The proteins are usually found at a concentration from 5 to 7% (w/v), and they are eluted near the dead time, which can put both the detection and quantification of the lower retained drug at risk. Furthermore, when the antiarrhythmics' serum concentration is appropriate, it is advisable to dilute samples before they are injected. The main reasons are to reduce the width of the protein band, prolong column life, prevent the need for frequent regeneration of the stationary phase, protect the column from an absorbed matrix, and improve reproducibility by avoiding variations in the retention times of the drugs under study. Thus, analyses were performed by diluting the samples in a proportion of 1:10 with the mobile phase containing 0.9% (w/v) NaCl during the determination of antiarrhythmics, because this allowed the appropriate concentrations of drug residues in serum samples to be monitored. With this strategy, the results we obtained from our study proved that the dilution was appropriate to detect the drugs being studied, and that no change in the retention times was observed after at least 550 consecutive injections of serum in a C18 column. 
Method Validation
Validation was done following the ICH guidelines (27) . The parameters evaluated were linearity, LOD, LOQ, precision, selectivity, and accuracy.
Linearity.-Linear calibration curves were constructed for each antiarrhythmic by measuring the peak areas after triplicate injection at seven increasing concentrations within its therapeutic range: 0.5, 1. (Table 1 ) was used. Regression coefficients were always r 2 > 0.999. LOD and LOQ.-The LOD (3a criterion) and LOQ (10d criterion) for antiarrhythmics were determined according to ICH guidelines (27) using 10 injections of serum blanks. Table 1 also shows the LODs and LODs in mg/L, and these values were appropriate for the monitoring of the three antiarrhythmics in patients' serum samples suitably diluted at 1:10, and they were below the therapeutic ranges.
Precision.-Intraday precision (Table 2) for the antiarrhythmics in the serum matrix diluted 1:10 was calculated by measuring the areas of the peaks obtained from the 10 injections of five test solutions on the same day. For each antiarrhythmic, intraday precision was determined for five different concentrations within the calibration ranges: 0.5, 2, 4, 6, and 8 mg/L for disopyramide and quinidine and 0.5, 1, 2.5, 5, and 10 mg/L for lidocaine.
Interday precision was calculated by measuring for disopyramide, quinidine, and lidocaine the areas of the peaks obtained from 10 injections of three test solutions (two injections/test solution) on 10 days over a 3-month period, made by different analysts, using different equipment, at three different drug concentrations. Table 2 interday precision (CV), which was always below 3.9%.
One-way analysis of variance calculations demonstrated that there were no differences between the averages of the 10 days.
Selectivity.-Six drug-free serum samples were selected as controls and processed directly in the chromatographic system. They were then analyzed to determine the extent to which endogenous components may interfere with the t R of the drug. No interference from endogenous compounds was found in the physiological matrixes studied (Figure 1a) .
Selectivity studies were performed with control spiked samples from eight different sources that were injected to demonstrate that there was no drug interference in the analysis of the three antiarrhythmic drugs. Antiarrhythmic pharmaceuticals are usually made up of the individual drug and some excipients. Only lidocaine is coadministered with corticosteroids, but under the experimental conditions proposed here, corticosteroids, such as hydrocortisone, triamcinolone, fluocinolone, and fludrocortisones, do not interfere with the antiarrhythmic. In fact, in the selected mobile phase, the retention times of these drugs are higher than 15 min.
Analysis of spiked serum samples.
-In order to demonstrate the accuracy of the method, standard solutions of each antiarrhythmic drug were prepared and subsequently added to controlled serum samples from healthy patients (not treated with either antiarrhythmics or any other pharmaceutical). Table 3 shows the recovery values (n = 10) for the antiarrhythmics at three different concentrations within the therapeutic range of each drug. The data obtained showed satisfactory recoveries (94.6-111%), with RSD <2.7%.
Analysis of Patient Serum Samples
The MLC procedure was used in the determination of antiarrhythmics in real serum samples from 52 patients treated with disopyramide, 92 treated with lidocaine, and 75 treated with quinidine. The same samples were analyzed using the reference method used in the Hospital. Serum samples were taken after administration and dilution of serum samples by 1:10 was performed with the mobile phase also containing 0.9% (w/v) NaCl. Figure 1a shows the chromatogram of a control serum sample. Figures 1b-d show the chromatograms of the serum samples isolated from the volunteer patients' blood. It can be observed that no protein or endogenous compound present in serum interfered with the determination of the antiarrhythmics.
Conclusions
Results indicate that the MLC procedure described here is useful for monitoring serum samples for the antiarrhythmics dysopyramide, lidocaine, and quinidine, with analysis times below 12 min. This method is sensitive enough for routine determination of these drugs at therapeutic levels that could be found in serum, with low LODs that are similar to those reported in the literature, bearing in mind that the serum samples were injected with no previous treatment, thereby preventing extraction losses during the evaporation and reconstitution steps). The developed MLC procedure is superior to traditional HPLC in that it can be used to determine the antiarrhythmics in serum samples by direct injection into the chromatographic system without any sample pretreatment. Finally, it can be concluded that our MLC method is simple and has enhanced reproducibility and reduced risk of contamination.
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